Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 11, 2018

SELL
$4.11 - $6.93 $55,772 - $94,040
-13,570 Closed
0 $0
Q4 2017

Feb 13, 2018

SELL
$1.74 - $4.34 $107,880 - $269,080
-62,000 Reduced 82.04%
13,570 $55,000
Q3 2017

Nov 14, 2017

BUY
$0.94 - $1.91 $71,035 - $144,338
75,570
75,570 $136,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.23B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Shepherd Kaplan Krochuk, LLC Portfolio

Follow Shepherd Kaplan Krochuk, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shepherd Kaplan Krochuk, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Shepherd Kaplan Krochuk, LLC with notifications on news.